Related Experiment Video
Updated: Apr 18, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
Published on: November 10, 2021
Cyclic nucleotide signalling in kidney fibrosis
Elisabeth Schinner1, Veronika Wetzl2, Jens Schlossmann3
1Pharmacology and Toxicology, University Regensburg, Regensburg 93053, Germany. elisabeth.schinner@chemie.uni-regensburg.de.
Abstract:
Kidney fibrosis is an important factor for the progression of kidney diseases, e.g., diabetes mellitus induced kidney failure, glomerulosclerosis and nephritis resulting in chronic kidney disease or end-stage renal disease. Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) were implicated to suppress several of the above mentioned renal diseases. In this review article, identified effects and mechanisms of cGMP and cAMP regarding renal fibrosis are summarized. These mechanisms include several signalling pathways of nitric oxide/ANP/guanylyl cyclases/cGMP-dependent protein kinase and cAMP/Epac/adenylyl cyclases/cAMP-dependent protein kinase. Furthermore, diverse possible drugs activating these pathways are discussed. From these diverse mechanisms it is expected that new pharmacological treatments will evolve for the therapy or even prevention of kidney failure.
Insights
Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) show potential in suppressing kidney fibrosis. Understanding their mechanisms may lead to new treatments for kidney disease progression and failure.
Area of Science:
- Nephrology
- Molecular Biology
- Pharmacology
Background:
- Kidney fibrosis is a key driver of progressive kidney diseases, including diabetic nephropathy, glomerulosclerosis, and nephritis.
- Chronic kidney disease and end-stage renal disease are often the result of unchecked renal fibrosis.
- Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) have demonstrated protective effects against various kidney diseases.
Purpose of the Study:
- To summarize the known effects and mechanisms of cAMP and cGMP in the context of renal fibrosis.
- To explore potential therapeutic strategies targeting these cyclic nucleotide pathways for kidney disease treatment.
Main Methods:
- This review synthesizes existing research on the roles of cAMP and cGMP in renal fibrosis.
- It examines signaling pathways involved, including the nitric oxide/guanylyl cyclase/cGMP-dependent protein kinase pathway and the cAMP/Epac/adenylyl cyclase/cAMP-dependent protein kinase pathway.
- Potential pharmacological agents that activate these pathways are discussed.
Main Results:
- cAMP and cGMP signaling pathways play significant roles in modulating renal fibrosis.
- Specific pathways identified include those involving nitric oxide, ANP, guanylyl cyclases, and protein kinases.
- Diverse drug targets that modulate these pathways have been identified.
Conclusions:
- The intricate mechanisms of cAMP and cGMP offer promising avenues for therapeutic intervention in kidney fibrosis.
- Targeting these pathways could lead to novel pharmacological treatments for the prevention and therapy of kidney failure.
- Further research into these pathways may revolutionize the management of progressive kidney diseases.
Related Concept Videos
Diabetic Nephropathy
Intracellular Signaling Cascades
Endocrine Signaling
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Chronic Kidney Disease III: Interprofessional Care
Nephrotic Syndrome I : Introduction

